

# Daniel J George

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2795478/publications.pdf>

Version: 2024-02-01

204  
papers

13,200  
citations

76196

40  
h-index

24915

109  
g-index

210  
all docs

210  
docs citations

210  
times ranked

13322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	13.9	2,412
2	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24.	0.8	1,590
3	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
4	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , 2016, 375, 2246-2254.	13.9	640
5	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.	0.8	584
6	Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401. <i>Journal of Clinical Oncology</i> , 2012, 30, 1534-1540.	0.8	436
7	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 378-388.	5.1	327
8	Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7841-7846.	3.3	282
9	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	1.3	280
10	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1120-1129.	0.8	267
11	Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2187-2196.	13.9	259
12	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
13	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , 2018, 73, 62-68.	0.9	164
14	The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480. <i>Clinical Cancer Research</i> , 2005, 11, 1815-1820.	3.2	152
15	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. <i>Lancet</i> , The, 2021, 397, 695-703.	6.3	146
16	Copper Signaling Axis as a Target for Prostate Cancer Therapeutics. <i>Cancer Research</i> , 2014, 74, 5819-5831.	0.4	143
17	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
18	Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin. <i>Journal of Clinical Oncology</i> , 2012, 30, 3402-3407.	0.8	138

#	ARTICLE	IF	CITATIONS
19	The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. <i>European Journal of Cancer</i> , 2010, 46, 517-525.	1.3	118
20	Magnetic Resonance Imagingâ€“Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 5548-5554.	3.2	111
21	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3391-3399.	0.8	110
22	Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma. <i>Academic Radiology</i> , 2005, 12, 347-357.	1.3	108
23	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. <i>European Urology</i> , 2015, 68, 891-898.	0.9	91
24	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	0.9	91
25	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.	0.8	83
26	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
27	Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 81, 228-236.	1.3	76
28	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinomaâ€“A Trial of the ECOGâ€“ACRIN Cancer Research Group (E2804). <i>Journal of Clinical Oncology</i> , 2015, 33, 2384-2391.	0.8	75
29	Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. <i>Cancer Research</i> , 2016, 76, 1892-1903.	0.4	72
30	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
31	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	0.8	72
32	Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. <i>Journal of Oncology Practice</i> , 2015, 11, 491-497.	2.5	67
33	A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3057-3066.	3.2	66
34	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
35	<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. , 2021, 9, e001792.		63
36	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1374-1380.	1.1	57

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer. <i>Cancer Medicine</i> , 2019, 8, 4644-4655.	1.3	55
38	Bone Marrow Biopsy: RNA Isolation with Expression Profiling in Men with Metastatic Castration-resistant Prostate Cancer Factors Affecting Diagnostic Success. <i>Radiology</i> , 2013, 269, 816-823.	3.6	54
39	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. <i>Oncotarget</i> , 2016, 7, 79828-79841.	0.8	53
40	A Phase II Trial of Tamsulosin in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	0.9	52
41	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
42	Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 877-881.	0.2	44
43	A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) A randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 428-437.	2.0	44
44	Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. <i>Clinical Cancer Research</i> , 2019, 25, 2963-2968.	3.2	43
45	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	0.9	42
46	Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301.	1.5	42
47	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. , 2022, 10, e003844.		42
48	The effect of gender and age on kidney cancer survival: Younger age is an independent prognostic factor in women with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e9-30.e13.	0.8	41
49	Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO. <i>Blood</i> , 2011, 118, 206-206.	0.6	40
50	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e15-530.e21.	0.8	38
51	Development of a Novel c-MET-Based CTC Detection Platform. <i>Molecular Cancer Research</i> , 2016, 14, 539-547.	1.5	37
52	Racial disparities in prostate cancer among black men: epidemiology and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 397-402.	2.0	37
53	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	0.9	36
54	Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confining Prostate Cancer?. <i>American Journal of Roentgenology</i> , 2016, 207, 87-95.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
56	Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure. <i>JAMA Oncology</i> , 2018, 4, 702.	3.4	35
57	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	1.4	35
58	Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , 2018, 24, 1554-1561.	3.2	34
59	Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. <i>BMC Cancer</i> , 2019, 19, 548.	1.1	34
60	Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 399-406.	0.6	34
61	A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	34
62	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32
63	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
64	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e513-e521.	0.9	31
65	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2022, 5, 18-29.	2.6	31
66	Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2019, 37, 212-212.	0.8	30
67	Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. <i>Clinical Cancer Research</i> , 2014, 20, 4218-4227.	3.2	29
68	Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. <i>BMC Cancer</i> , 2015, 15, 371.	1.1	29
69	Emerging treatment options for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2012, 72, 338-349.	1.2	28
70	Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040.	2.0	28
71	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4517-4517.	0.8	28
72	Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. <i>Biosensors and Bioelectronics</i> , 2020, 162, 112250.	5.3	27

#	ARTICLE	IF	CITATIONS
73	Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 753s-757s.	3.2	25
74	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	0.9	25
75	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
76	Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4520.	0.8	25
77	Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 418-424.	0.8	24
78	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. <i>Cancer</i> , 2020, 126, 4485-4497.	2.0	24
79	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. <i>Biomarker Research</i> , 2021, 9, 14.	2.8	24
80	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. <i>Cancer</i> , 2022, 128, 966-974.	2.0	24
81	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173.	3.2	23
82	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	1.9	22
83	Department of Defense Prostate Cancer Clinical Trials Consortium: A New Instrument for Prostate Cancer Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 51-57.	0.9	21
84	Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 79.e15-79.e22.	0.8	21
85	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
86	A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 2954-2965.	2.0	21
87	Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 731-743.	2.3	20
88	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 680-688.	2.0	20
89	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 510-518.	0.8	18
90	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	1.5	18



#	ARTICLE	IF	CITATIONS
91	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. <i>European Urology Oncology</i> , 2021, 4, 948-954.	2.6	18
92	A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5518-5518.	0.8	18
93	Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 110.e1-110.e9.	0.8	17
94	Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e159-e166.	0.9	17
95	Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 1063-1069.	1.6	17
96	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1040-1050.	1.5	17
97	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e1-813.e9.	0.8	16
98	Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 118-118.	0.8	16
99	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 80.	2.8	16
100	Combination antiangiogenic tyrosine kinase inhibition and anti-EPD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. <i>Cancer Medicine</i> , 2021, 10, 2341-2349.	1.3	15
101	PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS763-TPS763.	0.8	15
102	What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. <i>Therapeutic Advances in Urology</i> , 2016, 8, 272-278.	0.9	14
103	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2019, 14, e0216934.	1.1	14
104	Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 588-592.	2.0	14
105	Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868.	3.2	14
106	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS366-TPS366.	0.8	14
107	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	3.2	14
108	The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 345-345.	0.8	14

#	ARTICLE	IF	CITATIONS
109	Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 524-530.	2.0	14
110	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 762-769.	2.0	13
111	Anti-angiogenic therapy in renal cell cancer. <i>BJU International</i> , 2007, 99, 1296-1300.	1.3	12
112	A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 319-327.	0.9	12
113	Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. <i>Advances in Therapy</i> , 2020, 37, 2083-2097.	1.3	12
114	Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127148.	1.0	12
115	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. <i>JCO Global Oncology</i> , 2021, 7, 495-505.	0.8	12
116	The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery. <i>Blood</i> , 2010, 116, 188-188.	0.6	12
117	Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. <i>Oncogene</i> , 2022, 41, 1140-1154.	2.6	12
118	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 11.	1.3	11
119	Racial Disparity in Response to Prostate Cancer Systemic Therapies. <i>Current Oncology Reports</i> , 2020, 22, 96.	1.8	11
120	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. <i>Oncolmmunology</i> , 2020, 9, 1773200.	2.1	10
121	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1271-1278.	0.4	10
122	Differential alternative RNA splicing and transcription events between tumors from African American and White patients in The Cancer Genome Atlas. <i>Genomics</i> , 2021, 113, 1234-1246.	1.3	10
123	A randomized, phase II efficacy assessment of multiple MET kinase inhibitors in metastatic papillary renal carcinoma (PRCC): SWOG S1500. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4599-TPS4599.	0.8	10
124	Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 28-37.e2.	0.9	9
125	Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival. <i>Carcinogenesis</i> , 2018, 39, 879-888.	1.3	9
126	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. <i>Journal of Clinical Oncology</i> , 2021, 39, e003281.		9



#	ARTICLE	IF	CITATIONS
127	Abstract CT313: An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx). <i>Cancer Research</i> , 2014, 74, CT313-CT313.	0.4	9
128	Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4513-4513.	0.8	9
129	Phase I study of pazopanib plus TH-302 in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 611-619.	1.1	8
130	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1137-e1141.	0.9	8
131	The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100183.	0.7	8
132	Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 730-730.	0.8	8
133	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	3.2	8
134	Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2184-2186.	0.8	7
135	Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4549-4549.	0.8	7
136	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4596-TPS4596.	0.8	7
137	Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. <i>Prostate</i> , 2017, 77, 385-395.	1.2	6
138	Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1106-1116.	1.2	6
139	Precision Medicine Approaches When Prostate Cancer Akts Up. <i>Clinical Cancer Research</i> , 2019, 25, 901-903.	3.2	6
140	Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2021, 17, OP.20.01082.	1.4	6
141	An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6619-6621.	3.2	6
142	Patient preferences and expectations of systemic therapy in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5083-5083.	0.8	6
143	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5100-TPS5100.	0.8	6
144	Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. <i>Cancer Investigation</i> , 2017, 35, 333-344.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 341-348.	0.9	5
146	The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 376-381.	1.0	5
147	Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4515-4515.	0.8	5
148	Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 96-96.	0.8	5
149	A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS268-TPS268.	0.8	5
150	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313.	2.0	5
151	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. <i>Asian Journal of Urology</i> , 2016, 3, 268-277.	0.5	4
152	The promise of immunotherapy in genitourinary malignancies. <i>Precision Clinical Medicine</i> , 2018, 1, 97-101.	1.3	4
153	An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma ( mRCC ). <i>Oncologist</i> , 2021, 26, e508-e511.	1.9	4
154	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	0.9	4
155	Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. <i>Future Oncology</i> , 2021, 17, 4431-4446.	1.1	4
156	DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5587-TPS5587.	0.8	4
157	Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 80-80.	0.8	4
158	Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 654-654.	0.8	4
159	Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021, 19, 64-72.	0.1	4
160	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	1.1	4
161	A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 58-64.	2.0	4
162	Cabozantinib in genitourinary malignancies. <i>Future Oncology</i> , 2017, 13, 755-765.	1.1	3

#	ARTICLE	IF	CITATIONS
163	Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 39-47.	1.1	3
164	Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3007-3007.	0.8	3
165	HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5602-5602.	0.8	3
166	Angiogenesis inhibitors in clinical oncology. <i>Update on Cancer Therapeutics</i> , 2006, 1, 429-434.	0.9	2
167	Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e509-e512.	0.9	2
168	Can I Get a Multidisciplinary Consult, Please? Systemic Immunotherapy and the Timing of Cytoreductive Nephrectomy. <i>European Urology Focus</i> , 2020, 6, 9-10.	1.6	2
169	Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e128-e132.	1.8	2
170	Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4612-4612.	0.8	2
171	Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5076-5076.	0.8	2
172	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 32-32.	0.8	2
173	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS760-TPS760.	0.8	2
174	Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2022, 13, 614-623.	0.5	2
175	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 513-523.	2.0	2
176	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1859-1860.	0.8	1
177	Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1752-1761.	1.2	1
178	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 509-513.	0.9	1
179	Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. <i>Future Oncology</i> , 2021, 17, 403-409.	1.1	1
180	AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.. <i>Journal of Clinical Oncology</i> , 2020, 38, 184-184.	0.8	1

#	ARTICLE	IF	CITATIONS
181	Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16532-e16532.	0.8	1
182	Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance).. Journal of Clinical Oncology, 2017, 35, 4522-4522.	0.8	1
183	Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 211-211.	0.8	1
184	Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 183-183.	0.8	1
185	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical Genitourinary Cancer, 2022, , .	0.9	1
186	Recent advances in the management of castration-resistant prostate cancer. Clinical Advances in Hematology and Oncology, 2013, 11, 181-3.	0.3	1
187	Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?. Clinical Advances in Hematology and Oncology, 2014, 12, 163-71.	0.3	1
188	The future of kidney cancer treatment. Clinical Advances in Hematology and Oncology, 2015, 13, 368-71.	0.3	1
189	Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clinical Advances in Hematology and Oncology, 2019, 17, 382-385.	0.3	1
190	Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma. Clinical Advances in Hematology and Oncology, 2020, 18, 204-207.	0.3	1
191	HOW DOES SIPULEUCELÂ€ ALTER OUR CLINICAL PRACTICE?. BJU International, 2010, 106, 945-946.	1.3	0
192	TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL. Neuro-Oncology Advances, 2019, 1, i10-i10.	0.4	0
193	Prostate Cancer National Summitâ€™s Call to Action. Clinical Genitourinary Cancer, 2019, 17, 161-168.	0.9	0
194	Impact of salvage therapy with APC8015F on the overall survival (OS) benefit achieved with sipuleucel-TÂ€in three phase III studies of metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, e15120-e15120.	0.8	0
195	Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.. Journal of Clinical Oncology, 2016, 34, 273-273.	0.8	0
196	The impact of continuing medical education (CME) programs in metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, e18280-e18280.	0.8	0
197	Longitudinal multiplex cytokine analysis for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with ipilimumab/nivolumab (I+N).. Journal of Clinical Oncology, 2020, 38, 731-731.	0.8	0
198	Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.. Journal of Clinical Oncology, 2020, 38, 5084-5084.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI).. Journal of Clinical Oncology, 2020, 38, 40-40.	0.8	0
200	Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 147-147.	0.8	0
201	Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.. Journal of Clinical Oncology, 2020, 38, 106-106.	0.8	0
202	Highlights in advanced prostate cancer from the 2013 American Urological Association Annual Meeting and the 2013 American Society of Clinical Oncology Annual Meeting: commentary. Clinical Advances in Hematology and Oncology, 2013, 11 Suppl 14, 16-22.	0.3	0
203	Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary. Clinical Advances in Hematology and Oncology, 2019, 17 Suppl 8, 17-19.	0.3	0
204	Setting a new standard for long-term survival in metastatic kidney cancer. Cancer, 2022, 128, 2058-2060.	2.0	0